Poolbeg Pharma (LON:POLB) Stock Price Breaks Below Two Hundred Day Moving Average – Here’s What Happened

Shares of Poolbeg Pharma PLC (LON:POLB) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of GBX 6.11 and traded as low as GBX 6. Poolbeg Pharma shares last traded at GBX 6, with a volume of 879,493 shares changing hands.

Analyst Ratings Changes

Separately, Shore Capital Group reissued a “house stock” rating on shares of Poolbeg Pharma in a report on Thursday, September 24th.

Poolbeg Pharma Price Performance

The company has a market cap of £45.81 million, a price-to-earnings ratio of -7.59 and a beta of 1.84. The company’s 50-day moving average is GBX 7.46 and its 200 day moving average is GBX 6.11.

Poolbeg Pharma (LON:POLB) last released its quarterly earnings data on Tuesday, September 29th. The company reported GBX (0.28) earnings per share for the quarter. Analysts predict that Poolbeg Pharma PLC will post -0.68 EPS for the current fiscal year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.